BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
下载
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [21] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    RHEUMATOLOGY, 2021, 60 (05) : 2256 - 2266
  • [22] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    Alberto Barragan, Jorge
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S110 - S110
  • [23] Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials
    Chen, Ying-Chou
    Yoo, Dae Hyun
    Lee, Chang Keun
    Li, Ko-Jen
    Won, Ji-Eon
    Wu, Wen-Shuo
    Zhong, Jinglin
    Nicolay, Claudia
    Walls, Chad Daniel
    Tanaka, Yoshiya
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (01) : 65 - 73
  • [24] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Smolen, J. S.
    Xie, L.
    Jia, B.
    Taylor, P. C.
    Burmester, G. R.
    Tanaka, Y.
    Elias, A.
    Cardoso, A.
    Ortmann, R.
    Walls, C.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1012 - 1012
  • [25] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study
    Caporali, Roberto
    Taylor, Peter C.
    Aletaha, Daniel
    Sanmarti, Raimon
    Takeuchi, Tsutomu
    Mo, Daojun
    Haladyj, Ewa
    Bello, Natalia
    Zaremba-Pechmann, Liliana
    Fang, Ying
    Dougados, Maxime
    RHEUMATOLOGY, 2024, 63 (10) : 2799 - 2809
  • [26] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Bird, Paul
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 23 - 23
  • [27] BARICITINIB VERSUS ADALIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: ANALYSIS OF PATIENTS ACHIEVING A MODERATE EULAR RESPONSE AT WEEK 4
    Kvien, T. K.
    van Riel, P.
    Rubbert-Roth, A.
    Blanco, R.
    Liu-Leage, S. S.
    Larsson, E.
    Lund, H.
    Lopez-Romero, P.
    Zaremba-Pechmann, L.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 794 - 795
  • [28] Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SED
    Choy, EHS
    Perdok, RJ
    Weinberg, TA
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4097 - 4097
  • [29] Efficacy and safety of baricitinib in patients with rheumatoid arthritis and inappropriate response to conventional disease-modifying anti-rheumatic drugs: 24-week phase 3 RA-BUILD study summary results
    Emery, P.
    Krogulec, M.
    Alonso, R. B.
    Rossini, M.
    Raeman, F.
    Walker, D.
    Ghizdavescu, A. P.
    Irto, I.
    Rentero, M. L.
    Casillas, M.
    De la Torre, I.
    Dougados, M.
    Larsson, E.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 20 - 21
  • [30] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 31 - 31
12345